Factors associated with the successful modification of antiretroviral therapy. HIV Outpatient Study Investigators.

Autor:	Weidle PJ; Epidemiology Branch, Division of HIV/AIDS Prevention Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, Centers for Disease Control, Atlanta, GA 30333, USA. pew6@cdc.gov, Lichtenstein KA, Moorman AC, Von Bargen JC, Greenberg KS, Palella FJ Jr, Holmberg SD
Jazyk:	angličtina
Zdroj:	AIDS (London, England) [AIDS] 2000 Mar 31; Vol. 14 (5), pp. 491-7.
DOI:	10.1097/00002030-200003310-00004
Abstrakt:	Objectives: To assess the characteristics of medication regimen modification and the influence of a commercial genotypic resistance assay on the short-term (3-12 weeks) viral load response (> or = 0.5 log reduction) in HIV-1-infected patients extensively treated with antiretroviral therapy (ART). Methods: A nested cohort study was performed in two clinics from the HIV Outpatient Study of 96 persons with a HIV-1 viral load of 10(4) log copies/ml or greater taking at least two antiretroviral medications. Results: Successful modification was associated with adding at least two new medications [relative risk (RR), 1.5; 95% confidence interval (CI), 1.1-2.2], adding a drug from a previously unused class of agents (RR, 2.0; CI, 1.4-2.9), the initiation of a non-nucleoside reverse transcriptase inhibitor (NNRTI) (RR, 1.7; CI, 1.2-2.4), but not substituting a protease inhibitor or the use of a commercial genotypic resistance assay. Conclusion: Incorporating a drug from a previously unused class or changing at least two new medications, but, within the confines of this study, not using a commercial genotypic resistance assay, was associated with the successful modification of ART as measured by a reduction in viral load.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu